Please login to the form below

Not currently logged in
Email:
Password:

Actavis Germany H1 2007 sales increase 21 per cent

Actavis Group, the Icelandic-headquartered generic pharmaceuticals company, has revealed that Germany has become its second-largest market, with EUR 35m in product sales in H1 FY07.

Actavis Group, the Icelandic-headquartered generic pharmaceuticals company, has revealed that Germany has become its second-largest market, with EUR 35m in product sales in H1 FY07.

With Actavis' third party division sales included in the results, total sales in Germany were EUR 66m in H1 FY07. Actavis' largest market is North America, which brought in sales of over EUR 500m in annual sales.

IMS data has also revealed that Actavis Deutschland is the seventh largest generic pharmaceuticals company in Germany, which is also Europe's largest generics market.

Even though market reforms and generic price erosion have reduced the attractiveness of the German market, Actavis has still increased its revenue growth in the region by 21 per cent, compared with H1 FY06 figures. The success has been attributed to Actavis' full product pipeline and sales force of 130 reps, which is set to increase.

The recent preferred partnership contract agreement with Allgemeine Ortskrankenkassen (AOK), Germany's largest General local health insurance provider, has helped ramp up sales. Actavis also provides over 40 products for the VdAK and the AEV insurance associations.

Actavis' deputy CEO, Sigurdur Oli Olafsson, said: "Going forward, we expect to see good growth in our German business, through an increasing number of new product launches, continued alliances with leading German insurance funds, as well as our important partnership arrangements with German generic companies for product supply."

22nd August 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Empowering Strategic Performance Ltd

OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...

Latest intelligence

White Paper for download - Explaining the price of your product
In this white paper, he breaks down the pricing options available to you, shares stories from his extensive experiences, and talks you through how to better define your pricing, step-by-step....
OPEN Health expands offering with the launch of a new Learning & Development specialist team
Enhanced expertise to deliver impactful internal training programmes for healthcare clients...
Figure 1 Clarivate
The changing nature of approvals – what does the future hold?
The 2019 CMR International Pharmaceutical R&D Factbook...

Infographics